Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 12,000 | 0 | 0 | 0 | 3,000 |
| Cost of Goods | N/A | N/A | N/A | N/A | 407 |
| Gross Profit | 12,000 | N/A | N/A | N/A | 2,593 |
| Operating Expenses | 55,736 | 47,883 | 33,847 | 16,483 | 48,579 |
| Operating Income | -43,736 | -47,883 | -33,847 | -16,483 | -45,579 |
| Interest Expense | 4,332 | 3,676 | 1,861 | 1,247 | 902 |
| Other Income | 3,980 | 275 | 4,117 | 759 | -177 |
| Pre-tax Income | -44,087 | -51,283 | -31,591 | -16,971 | -46,658 |
| Income Tax | 133 | 99 | N/A | N/A | 408 |
| Net Income Continuous | -44,220 | -51,382 | -31,591 | -16,971 | -47,066 |
| Minority Interests | N/A | N/A | -269 | -773 | -50 |
| Net Income | $-44,220 | $-51,382 | $-31,322 | $-16,198 | $-47,016 |
| EPS Basic Total Ops | -21.52 | -29.44 | -19.20 | -16.00 | -58.00 |
| EPS Basic Continuous Ops | -21.51 | -29.47 | -19.40 | -17.66 | -57.96 |
| EPS Diluted Total Ops | -21.52 | -29.44 | -19.20 | -16.00 | -58.00 |
| EPS Diluted Continuous Ops | -21.51 | -29.47 | -19.40 | -17.66 | -57.96 |
| EPS Diluted Before Non-Recurring Items | -21.52 | -29.44 | -19.20 | -16.00 | -29.60 |
| EBITDA(a) | $-43,387 | $-47,551 | $-33,564 | $-16,186 | $-45,134 |